09/19/2018 /
A research team led by CURE Grantee Dr. Jeong Ho Lee identified a mutation in the BRAF gene that causes intrinsic epileptogenicity in pediatric brain tumors.
09/19/2018 /
The purpose of the study is to evaluate the effect of stable co-administered oxcarbazepine (OXC), on the pharmacokinetics (PK), safety, tolerability of padsevonil (PSL) and the plasma PK of PSL metabolites, UCB1431322-000 and UCB1447499-000, in study participants with epilepsy compared with study participants co-medicated with stable doses of levetiracetam (LEV), lamotrigine (LTG) or brivaracetam (BRV) therapy.
09/18/2018 /
The completion of this project should permit the unveiling of a new neuronal mechanism supporting the lack of conscious experience during absences and pave the way for new clinical non-invasive strategies to interrupt ongoing seizure activity.
09/18/2018 /
Becoming familiar with this new language can enable you and your doctor to better communicate about your treatment options, triggers to avoid, and what to expect in the future.
09/17/2018 /
Researchers say pigs are promising preclinical research models for hippocampal-dependent human memory disorders.
09/14/2018 /
Supernus Pharmaceuticals said it has agreed to acquire Biscayne Neurotherapeutics for up to $185 million, in a deal that adds a Phase I epilepsy candidate to the buyer’s pipeline of treatments for central nervous system disorders.
The epilepsy candidate, which Supernus will rename SPN-817, uses a novel synthetic form of huperzine A, an acetyl cholinesterase inhibitor that according to the company has a novel mechanism of action and has shown anticonvulsant activity in preclinical models for partial seizures and Dravet Syndrome.
09/13/2018 /
Discover the latest about what’s happening at CURE and in our community in the September 2018 CURE Update from Chief Scientific Officer, Dr. Laura Lubbers!
